Erbez Georgia 4
4 · Sierra Oncology, Inc. · Filed Jul 1, 2022
Insider Transaction Report
Form 4
Erbez Georgia
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2022-07-01−18,000→ 0 totalExercise: $17.76Exp: 2031-06-02→ Common Stock (18,000 underlying)
Footnotes (2)
- [F1]The options vest at the rate of 2.778% monthly, beginning on the one-month anniversary of the grant date, with 100% vested on the three-year anniversary of the grant date, subject to the provision of service by the Reporting Person to the Issuer on each vesting date.
- [F2]Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.